Cargando…
Production of Recombinant Pharmaceutical Proteins
The proteins produced in the body control and mediate the metabolic processes and help in its routine functioning. Any kind of impairment in protein production, such as production of mutated protein, or misfolded protein, leads to disruption of the pathway controlled by that protein. This may manife...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7120688/ http://dx.doi.org/10.1007/978-981-10-0875-7_4 |
_version_ | 1783515030264741888 |
---|---|
author | Gupta, Varsha Sengupta, Manjistha Prakash, Jaya Tripathy, Baishnab Charan |
author_facet | Gupta, Varsha Sengupta, Manjistha Prakash, Jaya Tripathy, Baishnab Charan |
author_sort | Gupta, Varsha |
collection | PubMed |
description | The proteins produced in the body control and mediate the metabolic processes and help in its routine functioning. Any kind of impairment in protein production, such as production of mutated protein, or misfolded protein, leads to disruption of the pathway controlled by that protein. This may manifest in the form of the disease. However, these diseases can be treated, by supplying the protein from outside or exogenously. The supply of active exogenous protein requires its production on large scale to fulfill the growing demand. The process is complex, requiring higher protein expression, purification, and processing. Each product needs unique settings or standardizations for large-scale production and purification. As only large-scale production can fulfill the growing demand, thus it needs to be cost-effective. The tools of genetic engineering are utilized to produce the proteins of human origin in bacteria, fungi, insect, or mammalian host. Usage of recombinant DNA technology for large-scale production of proteins requires ample amount of time, labor, and resources, but it also offers many opportunities for economic growth. After reading this chapter, readers would be able to understand the basics about production of recombinant proteins in various hosts along with the advantages and limitations of each host system and properties and production of some of the important pharmaceutical compounds and growth factors. |
format | Online Article Text |
id | pubmed-7120688 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
record_format | MEDLINE/PubMed |
spelling | pubmed-71206882020-04-06 Production of Recombinant Pharmaceutical Proteins Gupta, Varsha Sengupta, Manjistha Prakash, Jaya Tripathy, Baishnab Charan Basic and Applied Aspects of Biotechnology Article The proteins produced in the body control and mediate the metabolic processes and help in its routine functioning. Any kind of impairment in protein production, such as production of mutated protein, or misfolded protein, leads to disruption of the pathway controlled by that protein. This may manifest in the form of the disease. However, these diseases can be treated, by supplying the protein from outside or exogenously. The supply of active exogenous protein requires its production on large scale to fulfill the growing demand. The process is complex, requiring higher protein expression, purification, and processing. Each product needs unique settings or standardizations for large-scale production and purification. As only large-scale production can fulfill the growing demand, thus it needs to be cost-effective. The tools of genetic engineering are utilized to produce the proteins of human origin in bacteria, fungi, insect, or mammalian host. Usage of recombinant DNA technology for large-scale production of proteins requires ample amount of time, labor, and resources, but it also offers many opportunities for economic growth. After reading this chapter, readers would be able to understand the basics about production of recombinant proteins in various hosts along with the advantages and limitations of each host system and properties and production of some of the important pharmaceutical compounds and growth factors. 2016-10-23 /pmc/articles/PMC7120688/ http://dx.doi.org/10.1007/978-981-10-0875-7_4 Text en © Springer Science+Business Media Singapore 2017 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | Article Gupta, Varsha Sengupta, Manjistha Prakash, Jaya Tripathy, Baishnab Charan Production of Recombinant Pharmaceutical Proteins |
title | Production of Recombinant Pharmaceutical Proteins |
title_full | Production of Recombinant Pharmaceutical Proteins |
title_fullStr | Production of Recombinant Pharmaceutical Proteins |
title_full_unstemmed | Production of Recombinant Pharmaceutical Proteins |
title_short | Production of Recombinant Pharmaceutical Proteins |
title_sort | production of recombinant pharmaceutical proteins |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7120688/ http://dx.doi.org/10.1007/978-981-10-0875-7_4 |
work_keys_str_mv | AT guptavarsha productionofrecombinantpharmaceuticalproteins AT senguptamanjistha productionofrecombinantpharmaceuticalproteins AT prakashjaya productionofrecombinantpharmaceuticalproteins AT tripathybaishnabcharan productionofrecombinantpharmaceuticalproteins |